What is the survival rate for breast cancer stage 1? What is the survival rate of breast cancer stage 3? What is the survival rate for basal cell carcinoma? What is the survival rate of adrenal cancer? What are the survival rates of pancreatic cancer? What is the B-cell lymphoma surviva...
Unilateral, clinically T2N0, squamous cell carcinoma of the tongue: surgical outcome analysis To determine the survival rate and analyse the predicting factors of recurrence in patients with unilateral, clinically T2N0 squamous cell carcinoma (SCC) ... YC Lim,EC Choi - 《International Journal of ...
Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence. Int Urol Nephrol 1991; 23: 13-25.de Riese W, Goldenberg K, Allhoff E, et al. Metastatic renal cell carcinoma (RCC): spon- taneous regression, long-term survival and late recurrence. Int ...
Eleven-Year Survival with Unresectable Metastatic PancreaticCarcinoma: A Roadmap to Long-term Survival for Metastatic Disease 来自 掌桥科研 喜欢 0 阅读量: 56 作者:BM Chue,BDL Course 摘要: Pancreatic cancer is often considered one of the most deadly cancers because it is typically discovered late ...
S. Growth rate of hepatic metastases in colorectal carcinoma. Br. J. Surg. 75, 641–644 (1988). CAS PubMed Google Scholar Spratt, J. S. Jr. & Spratt, T. L. Rates of growth of pulmonary metastases and host survival. Ann. Surg. 159, 161–171 (1964). PubMed PubMed Central ...
These dissemination rate parameters represent the combination of; the rate of release of CTCs, their survival probability in the circulatory system and the probability of forming a metastasis in a downstream site. In our model, the four metastatic sites: bone, lung, liver and brain are ...
Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case s... The debate surrounding the acceptance of progression-free survival (PFS) as an intermediate endpoint to overall survival (OS) has grown in ...
Signet ring cell carcinoma0(0)2 (3.13) Others1 (10.00)2 (4.00)1 (8.33)4 (6.25) Empty Cell Tumor grade0.080.01 Well-differentiated0(0)1 (2.00)0(0)2 (3.13) Moderately differentiated8 (80.00)39 (78.00)6 (50.00)46 (71.88) Poorly differentiated/Anaplastic2 (20.00)5 (10.00)2 (16.67)9...
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 13, 1055–1062 (2008). Article CAS Google Scholar Claesson-Welsh, L., Dejana, E. & McDonald, D. M. ...
Prostate cancer (PCa) poses a significant clinical burden as the second most common malignancy in men and the third most common cause of cancer-related death worldwide1. While most localized PCa can be cured, the 5-year survival rate for patients presenting with metastatic disease is as low ...